Budesonide (Inhaled)
Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Maintenance treatment of asthma as prophylactic therapy (Flexhaler DPI) | Adults and children ≥6 years | Controller monotherapy or with LABA | FDA Approved |
| Maintenance treatment of asthma and as a treatment to reduce or replace oral corticosteroids (Respules nebulisation) | Children 1–8 years | Controller therapy via jet nebuliser | FDA Approved |
Budesonide is a cornerstone inhaled corticosteroid with the broadest age range of any ICS in the United States, spanning from 12 months (nebulisation) through adulthood (DPI). It is the only ICS with an FDA-approved nebulised formulation for young children, making it uniquely important in paediatric asthma management. Budesonide is distinguished from fluticasone propionate by its higher oral bioavailability (~10% vs <1%), shorter half-life (2–3 h vs ~7.8 h), and the most extensive human pregnancy safety data of any ICS, leading GINA to designate it as the preferred ICS in pregnancy. It is available as a mixture of two epimers (22R and 22S), with the 22R form being twice as pharmacologically active.
Croup (laryngotracheobronchitis) — nebulised budesonide 2 mg single dose: Evidence quality — High. Nebulised budesonide is widely used and supported by multiple RCTs for moderate-to-severe croup, reducing symptom scores and hospital admission rates.
COPD (as ICS-LABA combination with formoterol): Evidence quality — High. Budesonide-formoterol (Symbicort) is FDA-approved for COPD. Inhaled budesonide alone is sometimes used off-label in COPD patients with eosinophilic phenotype or frequent exacerbations.
Dosing
Pulmicort Flexhaler (DPI) — Asthma Maintenance
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Mild-moderate asthma — adults ≥18 y, ICS-naive or low prior ICS | 180–360 mcg BID | 180–360 mcg BID | 720 mcg BID | 180 mcg BID may suffice for mild disease; titrate to lowest effective dose Onset within 24 h; max benefit 1–2 weeks |
| Moderate-severe asthma — adults ≥18 y, higher ICS requirement | 360 mcg BID | 360–720 mcg BID | 720 mcg BID | Consider ICS-LABA combination if not controlled at 720 mcg BID Step down after 3 months of stability per GINA |
| Paediatric asthma — children 6–17 y | 180 mcg BID | 180–360 mcg BID | 360 mcg BID | 360 mcg BID starting dose may be appropriate in some patients Monitor growth velocity with stadiometry |
Pulmicort Respules (Nebulisation) — Paediatric Asthma (Ages 1–8 y)
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Previous therapy with bronchodilators alone | 0.5 mg/day | 0.25–0.5 mg/day | 0.5 mg/day | Once daily or divided BID via jet nebuliser Do not use ultrasonic nebulisers |
| Previous therapy with inhaled corticosteroids | 0.5 mg/day | 0.25–0.5 mg/day | 1 mg/day | Titrate to lowest effective dose May give once daily or divided BID |
| Previous therapy with oral corticosteroids | 1 mg/day | 0.5–1 mg/day | 1 mg/day | Once daily or divided BID; taper oral steroids slowly Wean prednisone ≥2 weeks after starting budesonide |
Budesonide is the only ICS with extensive human pregnancy safety data (Swedish Medical Birth Registry data on >2,000 early-pregnancy exposures in the original analysis, with subsequent analyses expanding this). Studies show no increase in congenital malformations with inhaled budesonide during early pregnancy. For this reason, GINA guidelines identify budesonide as the preferred ICS during pregnancy. Uncontrolled asthma during pregnancy carries greater risk to both mother and foetus than continued ICS use, so treatment should not be discontinued.
Pharmacology
Mechanism of Action
Budesonide is a synthetic non-halogenated glucocorticoid with potent topical anti-inflammatory activity. It exists as a racemic mixture of two epimers, 22R and 22S, which do not interconvert in vivo. The 22R epimer has approximately twice the glucocorticoid receptor binding affinity of the 22S form. Upon binding to intracellular glucocorticoid receptors, the activated complex translocates to the nucleus and modulates transcription of anti-inflammatory genes while suppressing pro-inflammatory mediator production. In the airways, budesonide inhibits multiple cell types involved in asthmatic inflammation including mast cells, eosinophils, macrophages, lymphocytes, and neutrophils. It suppresses production of cytokines, leukotrienes, and prostaglandins, and reduces airway hyperresponsiveness, mucosal oedema, and mucus hypersecretion. A unique pharmacological feature of budesonide is its ability to form intracellular fatty acid esters (budesonide-oleate) within airway epithelial cells, creating a local depot effect that prolongs pulmonary residence time beyond what its relatively short plasma half-life would suggest.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | Oral bioavailability ~10% (after first-pass); inhaled systemic bioavailability ~39% of delivered dose (Turbuhaler data); Tmax 15–30 min post-inhalation (DPI) | Higher oral bioavailability than fluticasone propionate (<1%); swallowed fraction contributes more to systemic exposure; mouth rinsing is important |
| Distribution | Vd ~3 L/kg; 85–90% plasma protein-bound; little binding to corticosteroid binding globulin; rapidly equilibrates with red blood cells | Moderate tissue distribution; protein binding lower than fluticasone (99%); free fraction is higher, partially offset by rapid clearance |
| Metabolism | Extensive first-pass hepatic metabolism via CYP3A4 to 6β-hydroxybudesonide and 16α-hydroxyprednisolone (both ≤1% activity of parent); negligible lung metabolism | CYP3A4 inhibitors (ritonavir, ketoconazole) increase systemic exposure; hepatic impairment doubles oral bioavailability but IV PK unchanged |
| Elimination | ~60% excreted in urine as metabolites; remainder in faeces; t½ 2–3 h (adults IV); total clearance ~1.2 L/min | Rapid clearance limits systemic accumulation; shorter half-life than fluticasone propionate contributes to less HPA suppression at equivalent anti-inflammatory doses |
Side Effects
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Respiratory infection | 34–38% (Respules paediatric trials) | Includes URTI, viral respiratory infections; high background rate in young children |
For the Flexhaler DPI, no adverse reaction reached ≥10% in the pooled placebo-controlled trials (N=226 active, N=230 placebo). The highest was nasopharyngitis at 9.3%.
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Nasopharyngitis | 9.3% (vs 8.3% placebo) | Most common event; small excess over placebo; self-limiting |
| Nasal congestion | 2.7% (vs 0.4% placebo) | Likely related to topical irritation; typically mild |
| Pharyngitis | 2.7% (vs 1.7% placebo) | Local steroid effect; mouth rinsing helps reduce |
| Allergic rhinitis | 2.2% (vs 1.3% placebo) | May be unmasked allergic condition; consider intranasal corticosteroid |
| Viral URTI | 2.2% (vs 1.3% placebo) | Background infection rate; not necessarily drug-related |
| Nausea | 1.8% (vs 0.9% placebo) | May relate to swallowed fraction; mouth rinsing reduces exposure |
| Viral gastroenteritis | 1.8% (vs 0.4% placebo) | Likely incidental; monitor for dehydration in young patients |
| Otitis media | 1.3% (vs 0.9% placebo) | Common in paediatric populations regardless of ICS use |
| Oral candidiasis | 1.3% (vs 0.4% placebo) | ICS class effect; dose-dependent; mouth rinsing is essential prevention |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| HPA axis suppression / adrenal crisis | Rare (dose-dependent) | Weeks to months at high doses | Cosyntropin stimulation test; taper dose; carry steroid emergency card during systemic steroid transition |
| Growth suppression in children | Common (1.1 cm reduction over 1 year at 200 mcg BID) | Months of treatment | Stadiometry monitoring; use lowest effective dose; growth velocity typically normalises after ICS discontinuation |
| Osteoporosis / decreased BMD | Uncommon (long-term, high dose) | Years | DEXA if risk factors present; calcium/vitamin D supplementation in high-risk patients |
| Glaucoma / cataracts | Uncommon (long-term) | Months to years | Ophthalmology referral for visual changes; close monitoring warranted per FDA PI |
| Anaphylaxis / hypersensitivity | Very rare (postmarketing) | Minutes | Discontinue immediately; standard anaphylaxis management; note milk protein allergy risk with Flexhaler formulation |
| Paradoxical bronchospasm | Very rare | Immediately after inhalation | Rescue SABA; discontinue budesonide; switch to alternative ICS or device |
In the Childhood Asthma Management Program (CAMP) trial, children treated with budesonide 200 mcg BID via a different Pulmicort DPI had a 1.1 cm reduction in growth compared with placebo at the end of 1 year. However, the difference did not increase further over 3 additional years of treatment, and growth velocities normalised after the initial year. Final adult height data suggested the effect was mostly limited to the first year of therapy and did not appear to be cumulative, though individual variability exists.
Drug Interactions
Budesonide is a substrate of CYP3A4. Its relatively rapid hepatic clearance (~1.2 L/min) means that CYP3A4 inhibitors can meaningfully increase systemic exposure. However, because budesonide has a shorter half-life and faster clearance than fluticasone propionate, the magnitude of interaction-related toxicity may be somewhat lower. No other clinically significant drug interactions have been identified with inhaled budesonide.
Monitoring
- Lung FunctionBaseline, 1–3 months, then q3–12 months
RoutineFEV1 or PEF to confirm response. Improvement may occur within 24 hours but full benefit takes 1–2 weeks. Step down after 3 months of stability. - Growth (Paediatric)Every 6–12 months
RoutineStadiometry in all children on ICS. CAMP trial showed 1.1 cm/year reduction at 200 mcg BID; effect did not increase beyond the first year. Use lowest effective dose. - Oropharyngeal HealthEach visit
RoutineInspect for oral candidiasis. Reinforce mouth rinsing and spitting after each inhalation. Treat with topical antifungals if needed. - HPA AxisIf high-dose ICS or adrenal symptoms
Trigger-basedMorning cortisol or cosyntropin stimulation if using ≥720 mcg BID chronically. In PI trials, 13% of patients on 800 mcg BID had abnormal cortisol response (<14.5 mcg/dL). - BMD & OcularLong-term high-dose, risk factors
Trigger-basedDEXA for osteoporosis risk factors. Ophthalmology referral for visual changes. Long-term ICS use associated with cataracts and glaucoma. - Inhaler/Nebuliser TechniqueEach visit
RoutineDPI: verify deep, forceful inhalation (flow-dependent delivery); device delivers ~40–50% of dose at 30 L/min vs full dose at 60 L/min. Nebuliser: use jet nebuliser only (not ultrasonic); face mask or mouthpiece; ~17% delivery at mouthpiece.
Contraindications & Cautions
Absolute Contraindications
- Primary treatment of status asthmaticus or acute asthma episodes requiring intensive measures
- Severe hypersensitivity to milk proteins (Flexhaler contains lactose with trace milk proteins)
- Hypersensitivity to budesonide or any excipient
Relative Contraindications (Specialist Input Recommended)
- Active pulmonary tuberculosis: Use only with appropriate anti-TB therapy
- Untreated systemic fungal, bacterial, viral, or parasitic infections
- Ocular herpes simplex
Use with Caution
- Hepatic impairment: Oral bioavailability doubles in cirrhosis (though IV PK unchanged); monitor for systemic corticosteroid effects
- Patients transferring from systemic corticosteroids: Risk of adrenal insufficiency; taper slowly
- Chickenpox or measles exposure in unimmunised patients
- Concurrent strong CYP3A4 inhibitors: Increased systemic budesonide exposure
Deaths due to adrenal insufficiency have occurred in asthmatic patients during and after transfer from systemic corticosteroids to inhaled corticosteroids. Recovery of HPA axis function may require several months after withdrawal from systemic steroids. Patients should carry a steroid warning card and may need supplementary systemic steroids during physiologic stress.
Patient Counselling
Purpose of Therapy
Budesonide is a daily controller medication that reduces inflammation in the airways to prevent asthma symptoms and attacks. It works gradually and does not provide immediate relief during an asthma episode. A rescue inhaler should always be available. Improvement may begin within 24 hours, but full benefit typically develops over 1–2 weeks of regular use.
How to Take
For Flexhaler (DPI): Hold upright and twist the base to load a dose (you will hear a click). Do not shake. Exhale away from the device, then inhale deeply and forcefully through the mouthpiece. You will not taste or feel the medication — this is normal. After inhaling, rinse your mouth with water and spit. For Respules (nebulisation): Use a jet nebuliser with an air compressor and face mask or mouthpiece. Do not use an ultrasonic nebuliser. Each ampule is for single use. Gently shake the ampule before opening. Nebulisation typically takes about 5 minutes.
Sources
- Pulmicort Flexhaler (budesonide inhalation powder) prescribing information. AstraZeneca. Revised 12/2018. FDA Label Primary source for DPI dosing, Table 1 adverse reaction data, PK parameters, growth data, and CYP3A4 interaction warnings.
- Pulmicort Respules (budesonide inhalation suspension) prescribing information. AstraZeneca. FDA Label Source for nebulisation dosing in children 1–8 years, paediatric PK data, and Respules-specific adverse reaction data.
- The Childhood Asthma Management Program Research Group. Long-term effects of budesonide or nedocromil in children with asthma. N Engl J Med. 2000;343(15):1054–1063. DOI CAMP trial (N=1,041; 4–9 years follow-up); primary source for growth velocity data (1.1 cm reduction at 1 year with budesonide 200 mcg BID).
- Pauwels RA, Lofdahl CG, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med. 1997;337(20):1405–1411. DOI Landmark trial demonstrating exacerbation reduction with budesonide plus formoterol; foundation for ICS-LABA combination therapy.
- Rabe KF, Pizzichini E, Stallberg B, et al. Budesonide/formoterol in a single inhaler for maintenance and relief in mild-to-moderate asthma (SYGMA 2). N Engl J Med. 2018;378(20):1865–1876. DOI Pivotal trial supporting budesonide-formoterol as-needed (SMART/MART) strategy now recommended by GINA for mild asthma.
- Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention. 2024 update. GINA Current international guidelines recommending budesonide as preferred ICS in pregnancy and defining low/medium/high dose classifications.
- Brattsand R, Miller-Larsson A. The role of intracellular esterification in budesonide once-daily dosing and airway selectivity. Clin Ther. 2003;25 Suppl C:C28–41. DOI Describes the unique intracellular fatty acid esterification of budesonide creating a local depot in airway cells, prolonging topical anti-inflammatory effect.
- Derendorf H, Nave R, Drollmann A, et al. Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma. Eur Respir J. 2006;28(5):1042–1050. DOI Comparative ICS pharmacokinetics review; source for budesonide oral bioavailability (~10%), clearance, and systemic availability data relative to other ICS agents.
- Thorsson L, Edsbacker S, Kallen A, et al. Pharmacokinetics and systemic activity of fluticasone via Diskus and pMDI, and of budesonide via Turbuhaler. Br J Clin Pharmacol. 2001;52(5):529–538. DOI Comparative PK study establishing budesonide systemic bioavailability (~39% via Turbuhaler) and head-to-head data with fluticasone propionate.
- Kallen B, Rydhstroem H, Aberg A. Congenital malformations after the use of inhaled budesonide in early pregnancy. Obstet Gynecol. 1999;93(3):392–395. DOI Swedish Medical Birth Registry analysis (>2,000 pregnancies) showing no increased malformation rate with inhaled budesonide; key safety data supporting GINA pregnancy recommendation.
- Pedersen S, Warner J, Wahn U, et al. Growth, systemic safety, and efficacy during 1 year of asthma treatment with different beclomethasone dipropionate formulations: an open-label, randomized comparison of extrafine and conventional aerosols in children. Pediatrics. 2002;109(6):e92. DOI Growth monitoring methodology reference relevant to ICS class; supports stadiometry as standard monitoring tool in paediatric ICS use.
- Szefler SJ, Baker JW, Uryniak T, et al. Comparative study of budesonide inhalation suspension and montelukast in young children with mild persistent asthma. J Allergy Clin Immunol. 2007;120(5):1043–1050. DOI Head-to-head trial demonstrating superiority of nebulised budesonide over montelukast for young children with persistent asthma.